Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CDC25A | P30304 | 9/20 | 0.37 |
| ▸ | CDC25B | P30305 | 4/20 | 0.35 |
| ▸ | CDC45 | O75419 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 2/20 | 0.33 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Loxanast SCHEMBL11406912 | 1.00 | FFAR3 (0.42) | FFAR3MAPTCDC25ACDC25BCDC45 | |
| Loxanast SCHEMBL2111026 | 1.00 | FFAR3 (0.42) | FFAR3MAPTCDC25ACDC25BCDC45 | |
| SCHEMBL11430440 | 0.85 | MAPT (0.38) | MAPTCDC25ACDC25BFNTAFNTB | |
| SCHEMBL11417830 | 0.85 | MAPT (0.38) | MAPTCDC25ACDC25BFNTAFNTB | |
| SCHEMBL11417836 | 0.85 | MAPT (0.38) | MAPTCDC25ACDC25BFNTAFNTB | |
| SCHEMBL11416386 | 0.81 | MME (0.40) | MAPTCDC25ACDC25BBLMTP53 | |
| SCHEMBL11417832 | 0.81 | MME (0.40) | MAPTCDC25ACDC25BBLMTP53 | |
| SCHEMBL11435968 | 0.81 | MAPT (0.39) | MAPTCDC25ACDC25BFNTAFNTB | |
| SCHEMBL11416390 | 0.81 | MME (0.40) | MAPTCDC25ACDC25BBLMTP53 | |
| SCHEMBL11429285 | 0.81 | MAPT (0.39) | MAPTCDC25ACDC25BFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119598741-A | IRI model-based electron density acquisition method and related system | 云南电网有限责任公司电力科学研究院 | 2025-03-11 | — | — | CN | claimed |
| CN-119517955-A | Graphite negative electrode material, preparation method thereof, negative electrode sheet and lithium ion battery | 溧阳紫宸新材料科技有限公司 | 2025-02-25 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| JP-55085537-A | — | — | None | — | — | JP | disclosed |
| JP-55085540-A | — | — | None | — | — | JP | disclosed |
| JP-55035014-A | — | — | None | — | — | JP | disclosed |
| JP-55085538-A | — | — | None | — | — | JP | disclosed |
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-0415697-B1 | Process for treating fatty acids | UNICHEMA CHEMIE BV (NL) | 1994-08-03 | — | — | EP | disclosed |
| US-4228304-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANTIULCER AGENTS, BACTERICIDES, ANTITHROMBOTIC AGENTS AND FOR LIVER DISORDERS, OR AS SURFACTANTS IN DETERGENTS AND OIL ADDITIVES | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 1980-10-14 | — | — | US | disclosed |
| JP-S5585538-A | SEPARATION OF CIS- AND TRANS-1-METHYL-4-ISOHEXYL- CYCLOHEXANECARBOXYLIC ACID | HISAMITSU PHARMACEUT CO INC | 1980-06-27 | — | — | JP | disclosed |
| JP-S5585537-A | SEPARATION OF CIS- AND TRANS-1-METHYL-4-ISOHEXYL- CYCLOHEXANECARBOXYLIC ACID | HISAMITSU PHARMACEUT CO INC | 1980-06-27 | — | — | JP | disclosed |
| JP-S5585540-A | SEPARATION OF CIS- AND TRANS-1-METHYL-4-ISOHEXYL- CYCLOHEXANECARBOXYLIC ACID | HISAMITSU PHARMACEUT CO INC | 1980-06-27 | — | — | JP | disclosed |
| JP-S5535014-A | PREPARATION OF CYCLOHEXANECARBOXYLIC ACID DERIVATIVE | HISAMITSU PHARMACEUT CO INC | 1980-03-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138977-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNND1, CTNNA1 | FFAR3 4823/4885MAPT 113/4885CDC25A 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.